| Janet Englund | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Treatment of Children Hospitalized with RSV Illness | MedImmune, Inc. | $90,500 | 11/12/07 |
| Carol A. Wallace | Early Aggressive Therapy in Juvenile Idiopathic Arthritis | NIAMS | $1,192,267 | 11/09/07 |
| F. Bruder Stapleton | Social and Physical Activity of Childhood Cancer Survivors | Fred Hutchinson Cancer Research Center | $5,072 | 11/08/07 |
| Craig Rubens | International Prematurity and Stillbirth Conference | Bill and Melinda Gates Foundation | $1,000,000 | 11/08/07 |
| Bonnie Ramsey | A Phase IV, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial of Pulmozyme in 3-5 Year Old Patients with Cystic Fibrosis | Genentech, Inc. | $1,237,609 | 11/05/07 |